A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis

Blood

Volumn 124, Issue 15, 2014, Pages 2325-2332

  Palladini, Giovanni ^a,b   Hegenbart, Ute ^c   Milani, Paolo ^a,b   Kimmich, Christoph ^c   Foli, Andrea ^a,b   Ho, Anthony D ^c   Rosin, Marta Vidus ^a,b   Albertini, Riccardo ^a   Moratti, Remigio ^a   Merlini, Giampaolo ^a,b   Schönland, Stefan ^c  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTHRACYCLINE; BENDAMUSTINE; BIOLOGICAL MARKER; BORTEZOMIB; CREATININE; DEXAMETHASONE; IXAZOMIB; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; IMMUNOGLOBULIN LIGHT CHAIN;

AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CHEMOTHERAPY; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DIALYSIS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOGLOBULIN LIGH CHAIN AMYLOIDOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PROTEINURIA; REMISSION; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; KIDNEY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; RISK FACTOR; TIME;

AGED; AMYLOIDOSIS; BIOLOGICAL MARKERS; COHORT STUDIES; DIALYSIS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84907658795     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-570010     Document Type: Article

References (24)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583-596.
2. Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013;121(26):5124-5130.
3. Leung N, Bridoux F, Hutchison CA, et al International Kidney and Monoclonal Gammopathy Research Group. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood. 2012;120(22):4292-4295.
4. Palladini G, Comenzo RL. The challenge of systemic immunoglobulin light-chain amyloidosis (AL). Subcell Biochem. 2012;65:609-642.
5. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29(14):1924-1933.
6. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751-3757.
7. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989-995.
8. Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541-4549.
9. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79(4):319-328.
10. Leung N, Glavey SV, Kumar S, et al. A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision? Haematologica. 2013;98(6):988-992.
11. Dember LM, Sanchorawala V, Seldin DC, et al. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease. Ann Intern Med. 2001;134(9 Pt 1):746-753.
12. Leung N, Dispenzieri A, Fervenza FC, et al. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis. Am J Kidney Dis. 2005;46(2):270-277.
13. Leung N, Dispenzieri A, Lacy MQ, et al. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation. Clin J Am Soc Nephrol. 2007;2(3):440-444.
14. Schönland SO, Hegenbart U, Bochtler T, et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood. 2012;119(2):488-493.
15. Arbustini E, Verga L, Concardi M, Palladini G, Obici L, Merlini G. Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid. 2002;9(2):108-114.
16. Brambilla F, Lavatelli F, Di Silvestre D, et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood. 2012;119(8):1844-1847.
17. Bochtler T, Hegenbart U, Heiss C, et al. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. Haematologica. 2008;93(3):459-462.
18. Palladini G, Russo P, Bosoni T, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem. 2009;55(3):499-504.
19. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107(19):2440-2445.
20. Palladini G, Barassi A, Klersy C, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood. 2010;116(18):3426-3430.
21. Kristen AV, Giannitsis E, Lehrke S, et al. Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood. 2010;116(14):2455-2461.
22. Moranne O, Watier L, Rossert J, Stengel B; GN-Progress Study Group. Primary glomerulonephritis: an update on renal survival and determinants of progression. QJM. 2008;101(3):215-224.
23. Pinney JH, Lachmann HJ, Bansi L, et al. Outcome in renal Al amyloidosis after chemotherapy. J Clin Oncol. 2011;29(6):674-681.
24. Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26(11):2317-2325.